S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.67 (+0.85%)
MSFT   318.43 (+0.85%)
META   303.17 (+0.99%)
GOOGL   132.94 (+1.59%)
AMZN   128.60 (+1.16%)
TSLA   248.05 (-0.87%)
NVDA   443.18 (+1.88%)
NIO   8.72 (-3.54%)
BABA   86.11 (-0.73%)
AMD   101.87 (-0.92%)
T   14.68 (-2.26%)
F   12.26 (-1.29%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.43%)
GE   108.48 (-1.87%)
DIS   81.30 (+0.31%)
AMC   8.09 (+1.25%)
PFE   33.70 (+1.60%)
PYPL   58.51 (+0.09%)
NFLX   378.84 (+0.33%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.67 (+0.85%)
MSFT   318.43 (+0.85%)
META   303.17 (+0.99%)
GOOGL   132.94 (+1.59%)
AMZN   128.60 (+1.16%)
TSLA   248.05 (-0.87%)
NVDA   443.18 (+1.88%)
NIO   8.72 (-3.54%)
BABA   86.11 (-0.73%)
AMD   101.87 (-0.92%)
T   14.68 (-2.26%)
F   12.26 (-1.29%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.43%)
GE   108.48 (-1.87%)
DIS   81.30 (+0.31%)
AMC   8.09 (+1.25%)
PFE   33.70 (+1.60%)
PYPL   58.51 (+0.09%)
NFLX   378.84 (+0.33%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.67 (+0.85%)
MSFT   318.43 (+0.85%)
META   303.17 (+0.99%)
GOOGL   132.94 (+1.59%)
AMZN   128.60 (+1.16%)
TSLA   248.05 (-0.87%)
NVDA   443.18 (+1.88%)
NIO   8.72 (-3.54%)
BABA   86.11 (-0.73%)
AMD   101.87 (-0.92%)
T   14.68 (-2.26%)
F   12.26 (-1.29%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.43%)
GE   108.48 (-1.87%)
DIS   81.30 (+0.31%)
AMC   8.09 (+1.25%)
PFE   33.70 (+1.60%)
PYPL   58.51 (+0.09%)
NFLX   378.84 (+0.33%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.67 (+0.85%)
MSFT   318.43 (+0.85%)
META   303.17 (+0.99%)
GOOGL   132.94 (+1.59%)
AMZN   128.60 (+1.16%)
TSLA   248.05 (-0.87%)
NVDA   443.18 (+1.88%)
NIO   8.72 (-3.54%)
BABA   86.11 (-0.73%)
AMD   101.87 (-0.92%)
T   14.68 (-2.26%)
F   12.26 (-1.29%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.43%)
GE   108.48 (-1.87%)
DIS   81.30 (+0.31%)
AMC   8.09 (+1.25%)
PFE   33.70 (+1.60%)
PYPL   58.51 (+0.09%)
NFLX   378.84 (+0.33%)
NASDAQ:ARDX

Ardelyx (ARDX) Stock Forecast, Price & News

$4.11
+0.03 (+0.74%)
(As of 02:39 PM ET)
Compare
Today's Range
$3.98
$4.24
50-Day Range
$3.44
$4.83
52-Week Range
$1.16
$5.13
Volume
2.65 million shs
Average Volume
6.05 million shs
Market Capitalization
$895.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Ardelyx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
99.8% Upside
$8.25 Price Target
Short Interest
Bearish
11.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
1.12mentions of Ardelyx in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$97,561 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.38) to ($0.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

262nd out of 969 stocks

Pharmaceutical Preparations Industry

103rd out of 453 stocks


ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Price History

ARDX Stock News Headlines

Ardelyx Says Japan Approves Tenapanor For Hyperphosphatemia
Ben Stein FREE Report: How Americans Are RUINING Retirement
There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!
Ardelyx (NASDAQ:ARDX) Shares Gap Up to $3.66
Analyst Expectations for Ardelyx's Future
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Ardelyx Q2 Loss Narrows
Ardelyx: Q2 Earnings Snapshot
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings
8/02/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
133
Year Founded
2007

Price Target and Rating

Average Stock Price Forecast
$8.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+102.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-67,210,000.00
Pretax Margin
-67.67%

Debt

Sales & Book Value

Annual Sales
$52.16 million
Book Value
$0.50 per share

Miscellaneous

Free Float
205,881,000
Market Cap
$888.87 million
Optionable
Optionable
Beta
1.17

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Michael G. RaabMr. Michael G. Raab (Age 58)
    Pres, CEO & Director
    Comp: $1.28M
  • Ms. Susan Rodriguez (Age 59)
    Chief Commercial Officer
    Comp: $760.77k
  • Dr. Laura A. Williams M.D. (Age 59)
    M.P.H., Chief Medical Officer
    Comp: $873.8k
  • Mr. Justin A. Renz CPA (Age 51)
    M.S.T., MBA, MST, Chief Financial & Operations Officer and Treasurer
  • Mr. Robert Felsch
    Sr. VP of Fin. & Chief Accounting Officer
  • Ms. Elizabeth A. Grammer Esq.Ms. Elizabeth A. Grammer Esq. (Age 59)
    Chief Legal & Admin. Officer and Sec.
  • Ms. Caitlin Lowie
    VP of Corp. Communications & Investor Relations
  • Ms. Charon Spencer Sr.
    Chief HR Officer
  • Mr. David P. Rosenbaum (Age 62)
    Chief Devel. Officer
  • Mr. Robert C. BlanksMr. Robert C. Blanks (Age 63)
    Chief Regulatory Affairs & Quality Assurance Officer













ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month price targets for Ardelyx's stock. Their ARDX share price forecasts range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 102.2% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2023?

Ardelyx's stock was trading at $2.85 at the beginning of the year. Since then, ARDX shares have increased by 43.2% and is now trading at $4.08.
View the best growth stocks for 2023 here
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The biopharmaceutical company had revenue of $22.33 million for the quarter, compared to analyst estimates of $15.88 million. Ardelyx had a negative net margin of 67.69% and a negative trailing twelve-month return on equity of 54.22%.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Ardelyx own?
What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $4.08.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $888.87 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Ardelyx have?

The company employs 133 workers across the globe.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -